Low Overexpression of HER-2/Neu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (Herceptin®) and Irinotecan as Therapy. A Phase II Trial

References

• Jemal A., Tiwari R. C., Murray T., Ghafoor A., Samuels A., Ward E., Feuer E. J., Thun M. J. Cancer statistics, 2004. [Review] CA. Cancer Journal for Clinicians 2004; 54(1)8–29
   PubMed Web of Science ®Google Scholar
• Petrelli N., Douglass H. O., Jr., Herrera L., Russell D., Stablein D. M., Bruckner H. W., Mayer R. J., Schinella R., Green M. D., Muggia F. M. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal tumor study group. J. Clin. Oncol. 1989; 7: 1419–1426, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Poon M. A., O'Connell M. J., Moertel C. G., Wieand H. S., Cullinan S. A., Everson L. K., Krook J. K., Mailliard J. A., Laurie J. A., Tschetter L. K. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol. 1989; 7: 1407–1418, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Saltz L. B., Cox J. V., Blanke C., Rosen L. S., Fehrenbacher L., Moore M. J., Maroun J. A., Ackland S. P., Locker P. K., Pirotta N., Elfring G. L., Miller L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N. Engl. J. Med. 2000; 343: 905–914, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Douillard J. Y., Cunningham D., Roth A. D., Navarro M., James R. D., Karasek P., Jandik P., Iverson T., Carmichael J., Alakl M., Gruia G., Awad L., Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000; 355: 1041–1047, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goldberg R. M., Sargent D. J., Morton R. F., Fuchs C. S., Ramanathan R. K., Williamson S. K., Findlay B. P., Pitot H. C., Alberts S. R. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004; 22(1)23–30, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cobbleigh M. A., Vogel C. L., Tripathy D., Robert N. J., Scholl S., Fehrenbacher L., Wolter J. M., Paton V., Shak S., Lieberman G., Slamon D. J. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999; 17: 2639–2648
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–182, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Pegram M., Hsu S., Lewis G., Pietras R., Beryt M., Sliwkowski M., Coombs D., Baly D., Kabbinavar F., Slamon D. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18: 2241–2251, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001; 344: 783–792, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Safran H., Ramanathan R., Schwartz J., King T., Steinoff M., Nauman C., Hesketh P., Ianitti D., Quirk D., Akerman P., Cioffi W., Rathore R., Moore T., Ramdin N., Mass R., Wolff R. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proc. Am. Soc. Clin. Oncol. 2001; 20: 130a, (abstract 517)
   Google Scholar
• Langer C. J., Adak S., Thor A. Phase II Eastern Cooperative Oncology Group (ECOG) pilot study of paclitaxel (P), carboplatin (C) and trastuzumab (T) in HER-2/neu advanced non-small cell lung cancer (NSCLC): early analysis of E2598. Proc. Am. Soc. Clin. Oncol. 2001; 20: 315a, (abstract 1257)
   Google Scholar
• Shirai H., Ueno E., Osaki M., Tatebe S., Ito H., Kaibara N. Expression of growth factors and their receptors in human early colorectal carcinomas: immunohistochemical study. Anticancer Res. 1995; 15: 2889–2894, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Yang J. L., Ow K. T., Russell P. J., Ham J. M., Crowe P. J. Higher expression of oncoproteins c-myc, c-erb B-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors. Ann. Surg. Oncol. 1996; 3: 574–579, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cunningham D., Pyrhonen S., James R. D., Punt C. J., Hickish T. F., Heikkila R., Johannesen T. B. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413–1418, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Contr. Clin. Trials. 1989; 10: 1–10, [CROSSREF]
   PubMedGoogle Scholar
• Gibaldi M., Perrier D. Pharmacokinetics. Marcel Dekker, Inc., New York 1982; 445–457
   Google Scholar
• Tokuda Y., Watanabe T., Omuro Y., Ando M., Katsumata N., Okumura A., Ohta M., Fujii H., Sasaki Y., Niwa T. Dose escalation and pharmacokinetic study of humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br. J. Cancer 1999; 81: 1419–1425, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pegram M. D., Lipton A., Hayes D. F., Weber B. L., Baselga J. M., Tripathy D., Baly D., Baughman S. A., Twaddell T., Glaspy J. A., Slamon D. J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 1998; 16: 2659–2671, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Hsu S. M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedure. J. Histochem. 1981; 29: 577–580
   PubMed Web of Science ®Google Scholar
• Tubbs R. R., Pettay J. D., Roche P. C., Stoler M. H., Jenkins R. B., Grogan T. M. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J. Clin. Oncol. 2001; 19: 2714–2721, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kapitanovic S., Radosevic S., Kapitanovic M. The expression of p185 HER-2/neu correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997; 112: 1103–1113, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kay E. W., Mulcahy H., Walsh C. B., Leader M., O'Donoghue D. Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology 1994; 25: 455–461, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Osaka T., Miyahara M., Uchino S., Inomata M., Kitano S., Kobayashi M. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998; 55: 548–555, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Xle R., Mathijssen R. H., Sparreboom A., Verweij J., Karlsson M. O. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J. Clin. Oncol. 2002; 20: 3293–3301, [CROSSREF]
   PubMed Web of Science ®Google Scholar